Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
LDP’s Social Security Commission Urges Govt to Revisit Off-Year Drug Price Revisions
The ruling Liberal Democratic Party’s (LDP) Research Commission on Social Security System on May 23 broadly agreed on a proposal prodding the government to reconsider “off-year” drug price revisions in light of inflation and other changes surrounding pharmaceuticals. The proposal…
To read the full story
Related Article
- Abolish Off-Year Revisions, No to Broader CEA Use: Eto Group to Ministers
June 7, 2024
- Japan Govt to Launch Public-Private Forum to Attract Investments
May 23, 2024
- LDP Project Team Finalizes Proposal, Pushes Rethink of Off-Year Revisions
May 22, 2024
- Off-Year Price Revisions Should Either Be Abolished or Revisited: LDP Lawmakers
May 21, 2024
- Government’s Pharma Innovation Panel to Propose Comprehensive Upgrades in Industry Policies
May 17, 2024
- LDP Healthcare Clique Urges Rethink of Rationale for Off-Year Drug Price Revisions
April 10, 2024
- New Govt Forum for Fighting Drug Loss Should Devise Strategies for Honebuto: LDP Members
March 6, 2024
- Pharma Groups Lobby Firmly against Expansion of CEA Price Adjustments: LDP Hearing
December 4, 2023
- LDP OKs Project Team Proposal to Boost Pharma Innovation, Create Command Tower
May 31, 2023
REGULATORY
- Japan Set to Compile Support Measures to Secure MCMs by Year-End
October 15, 2026
- Japan to Weigh Necessary Measures for FY2027 Revision: PM
October 15, 2026
- Japan Eyes Multi-Year Funding to Secure MCMs: Takaichi
October 14, 2026
- Pharma Continues Reform Push at 2nd Public-Private Subgroup Meeting
October 13, 2026
- AbbVie’s TrenibotE Up for Review on Oct. 26, Aquipta on Agenda Too
October 13, 2026
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…